The PD-1 inhibitors, pembrolizumab and nivolumab, were the earliest drugs to show durable responses and improved survival in patients with R/M HNSCC, leading to approval by the Food and Drug Administration (FDA). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.